This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rodés, B.
Right arrow Articles by González-Lahoz, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rodés, B.
Right arrow Articles by González-Lahoz, J.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, April 2000, p. 1370-1374, Vol. 38, No. 4
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Emergence of Drug Resistance Mutations in Human Immunodeficiency Virus Type 2-Infected Subjects Undergoing Antiretroviral Therapy

Berta Rodés,1 Africa Holguín,1 Vincent Soriano,1,* Manuela Dourana,2 Kamal Mansinho,3 Francisco Antunes,2 and Juan González-Lahoz1

Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain,1 and Service of Infectious Diseases, Hospital Santa Maria,2 and Service of Infectious Diseases, Hospital Egas Moniz,3 Lisbon, Portugal

Received 19 August 1999/Returned for modification 16 November 1999/Accepted 10 January 2000

The reverse transcriptase (RT) and protease genes from 12 human immunodeficiency virus type 2 (HIV-2)-infected individuals who had been exposed to antiretroviral drugs for longer than 6 months were examined for the presence of mutations which could be involved in drug resistance. Four individuals carried virus genotypes with amino acid substitutions potentially associated with resistance to nucleoside analogues: two at codon 70 (Kright-arrowR) and two at codon 184 (Mright-arrowV). Moreover, the latter two patients harbored a codon Q151M mutation which is associated to multidrug resistance in HIV-1, and one of these subjects carried some of the typically linked mutations at codons 65 and 69. With regard to the protease inhibitors, substitutions associated with resistance to protease inhibitors at codon 46 were observed in all individuals. Moreover, minor resistance mutations, as well as new ones of unknown meaning, were often seen in the protease gene. In conclusion, amino acid changes in the HIV-2 RT and protease genes which could be associated with drug resistance seem to occur at positions identical to those for HIV-1.

* Corresponding author. Mailing address: Service of Infectious Diseases, Hopital Carlos III, Instituto de Salud Carlos III, C/Rafael Calvo 7, 2° A, 28010 Madrid, Spain. Phone: 34-91-4532500, x2661. Fax: 34-91-7336614. E-mail: vsoriano{at}dragonet.es.

Journal of Clinical Microbiology, April 2000, p. 1370-1374, Vol. 38, No. 4
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Ntemgwa, M. L., Toni, T. d., Brenner, B. G., Camacho, R. J., Wainberg, M. A. (2009). Antiretroviral Drug Resistance in Human Immunodeficiency Virus Type 2. Antimicrob. Agents Chemother. 53: 3611-3619 [Full Text]  
  • Jallow, S., Alabi, A., Sarge-Njie, R., Peterson, K., Whittle, H., Corrah, T., Jaye, A., Cotten, M., Vanham, G., McConkey, S. J., Rowland-Jones, S., Janssens, W. (2009). Virological Response to Highly Active Antiretroviral Therapy in Patients Infected with Human Immunodeficiency Virus Type 2 (HIV-2) and in Patients Dually Infected with HIV-1 and HIV-2 in The Gambia and Emergence of Drug-Resistant Variants. J. Clin. Microbiol. 47: 2200-2208 [Abstract] [Full Text]  
  • Ntemgwa, M. L., Toni, T. d., Brenner, B. G., Oliveira, M., Asahchop, E. L., Moisi, D., Wainberg, M. A. (2009). Nucleoside and Nucleotide Analogs Select in Culture for Different Patterns of Drug Resistance in Human Immunodeficiency Virus Types 1 and 2. Antimicrob. Agents Chemother. 53: 708-715 [Abstract] [Full Text]  
  • Desbois, D., Roquebert, B., Peytavin, G., Damond, F., Collin, G., Benard, A., Campa, P., Matheron, S., Chene, G., Brun-Vezinet, F., Descamps, D., for the French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2, (2008). In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors. Antimicrob. Agents Chemother. 52: 1545-1548 [Abstract] [Full Text]  
  • Masse, S., Lu, X., Dekhtyar, T., Lu, L., Koev, G., Gao, F., Mo, H., Kempf, D., Bernstein, B., Hanna, G. J., Molla, A. (2007). In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 2 with Decreased Susceptibility to Lopinavir. Antimicrob. Agents Chemother. 51: 3075-3080 [Abstract] [Full Text]  
  • Held, D. M., Kissel, J. D., Thacker, S. J., Michalowski, D., Saran, D., Ji, J., Hardy, R. W., Rossi, J. J., Burke, D. H. (2007). Cross-Clade Inhibition of Recombinant Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus SIVcpz Reverse Transcriptases by RNA Pseudoknot Aptamers. J. Virol. 81: 5375-5384 [Abstract] [Full Text]  
  • Ntemgwa, M., Brenner, B. G., Oliveira, M., Moisi, D., Wainberg, M. A. (2007). Natural Polymorphisms in the Human Immunodeficiency Virus Type 2 Protease Can Accelerate Time to Development of Resistance to Protease Inhibitors. Antimicrob. Agents Chemother. 51: 604-610 [Abstract] [Full Text]  
  • Rodes, B., Sheldon, J., Toro, C., Jimenez, V., Alvarez, M. A., Soriano, V. (2006). Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother 57: 709-713 [Abstract] [Full Text]  
  • Damond, F., Brun-Vezinet, F., Matheron, S., Peytavin, G., Campa, P., Pueyo, S., Mammano, F., Lastere, S., Farfara, I., Simon, F., Chene, G., Descamps, D. (2005). Polymorphism of the Human Immunodeficiency Virus Type 2 (HIV-2) Protease Gene and Selection of Drug Resistance Mutations in HIV-2-Infected Patients Treated with Protease Inhibitors. J. Clin. Microbiol. 43: 484-487 [Abstract] [Full Text]  
  • Plantier, J.-C., Gueudin, M., de Oliveira, F., Damond, F., Lemee, V., Brun-Vezinet, F., Simon, F. (2004). Rapid Discrimination between Human Immunodeficiency Virus Type 2 Groups A and B by Real-Time PCR. J. Clin. Microbiol. 42: 5866-5870 [Abstract] [Full Text]  
  • Colson, P., Henry, M., Tourres, C., Lozachmeur, D., Gallais, H., Gastaut, J. A., Moreau, J., Tamalet, C. (2004). Polymorphism and Drug-Selected Mutations in the Protease Gene of Human Immunodeficiency Virus Type 2 from Patients Living in Southern France. J. Clin. Microbiol. 42: 570-577 [Abstract] [Full Text]  
  • Reeves, J. D., Doms, R. W. (2002). Human immunodeficiency virus type 2. J. Gen. Virol. 83: 1253-1265 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»